Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.71 |
| ▸ | AGPAT2 | O15120 | 7/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.61 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.61 |
| ▸ | AMD1 | P17707 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410637 | 0.88 | RAB9A (0.83) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12218261 | 0.86 | RAB9A (0.76) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12218264 | 0.86 | RAB9A (0.76) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL4523617 | 0.85 | RAB9A (0.73) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13963083 | 0.83 | RAB9A (0.71) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13963078 | 0.83 | RAB9A (0.71) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14028305 | 0.83 | RAB9A (1.00) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3500070 | 0.83 | CYP1A2 (1.00) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13963108 | 0.83 | CYP1A2 (0.69) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13963092 | 0.83 | RAB9A (0.61) | RAB9ANPC1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | RAB9A 1024/4885NPC1 2993/4885CYP1A2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.